Printer Friendly

U.S. BIOSCIENCE NAMES RUSSELL MCLAUCHLAN PRESIDENT

 U.S. BIOSCIENCE NAMES RUSSELL MCLAUCHLAN PRESIDENT
 WEST CONSHOHOCKEN, Pa., April 27 /PRNewswire/ -- Russell C.


McLauchlan has been named president and chief operating officer of U.S. Bioscience Inc. (AMEX: UBS), a pharmaceutical company specializing in new treatments for cancer and related diseases. He will be responsible for the company's worldwide commercial activities including sales, marketing, business development and manufacturing. He will report to Philip S. Schein, M.D., chairman and chief executive officer, who had also held the title of president.
 McLauchlan spent nearly 20 years with the American Cyanamid Co., most recently serving as vice president and general manager of Lederle Pharmaceuticals, where he had profit and loss responsibility for that operating unit. Earlier at Cyanamid he held a number of senior marketing and sales positions in the United States and abroad. For the three years prior to joining U.S. Bioscience, he was president and chief operating officer of Immunomedics Inc., where he directed the development and marketing of products to diagnose and treat cancer.
 Dr. Schein noted that McLauchlan's in-depth industry background "will be of immense value to U.S. Bioscience as we move closer to becoming an integrated pharmaceutical company. His experience in managing the development and marketing of products to treat cancer is particularly relevant to our company's business focus."
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life of patients with cancer and allied diseases. The company's portfolio includes a broad spectrum of cancer drugs, including four products in the final stages of development. One compound, altretamine, is marketed under the name Hexalen(R) in the United States.
 -0- 4/27/92
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503/
 (UBS) CO: U.S. Bioscience ST: Pennsylvania IN: MTC SU: PER


MM-DG -- SJ001 -- 2919 04/27/92 08:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1992
Words:316
Previous Article:VIATECH PROJECTS FIRST QUARTER RESULTS AND ANNOUNCES STOCK BUYBACK
Next Article:AT&T PARADYNE ANNOUNCES PRICE REDUCTION, NEW COST-EFFECTIVE MODEM AND ENHANCEMENTS FOR COMSPHERE SERIES


Related Articles
IMMUNOMEDICS AWARDED PATENT FOR IMAGING AND THERAPEUTIC AGENTS
U.S. BIOSCIENCE OBTAINS RIGHTS TO SELL OVARIAN CANCER DRUG IN EUROPE AND ISRAEL
IMMUNOMEDICS ELECTS A. E. COHEN TO BOARD OF DIRECTORS AND PLANS TO APPOINT NEW PRESIDENT
U.S. BIOSCIENCE NAMES BROWN, VOGEL TO SENIOR MANAGEMENT POSTS
/C O R R E C T I O N -- U.S. BIOSCIENCE/
DISTINGUISHED ONCOLOGIST JOINS BOARD OF DIRECTORS OF U.S. BIOSCIENCE
U.S. BIOSCIENCE NAMES AYER-PTASZEK VICE PRESIDENT - MARKETING
SCHERING-PLOUGH AND U.S. BIOSCIENCE
BioFlorida Appoints Russell Allen as Organization's New President.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters